Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NIFK (FHA domain) interacting nucleolar phosphoprotein pseudogene 1 (NIFKP1) is classified as a **pseudogene** in the human genome[3][9]. Pseudogenes are nonfunctional segments of DNA that are similar to known protein-coding genes, but are generally unable to produce functional protein products due to disruptive mutations such as frameshifts or premature stop codons[5]. NIFKP1 shows sequence similarity to the functional gene *NIFK*, which encodes a nucleolar protein that interacts with the FHA domain of the Ki-67 antigen and is implicated in cell cycle regulation[1][2]. However, as a pseudogene, NIFKP1 does not encode a functional protein and is therefore not a therapeutic target, nor does it have established biological functions, disease roles, or known drug interactions[3][9][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NIFK (FHA domain) interacting nucleolar phosphoprotein pseudogene 1 (NIFKP1).